Andere Sprachen Clover Biopharmaceuticals, Ltd.

Aktien

A3C6A8

KYG2280A1076

2197

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:22 29.04.2024			% 5 Tage	% 1. Jan.
0,345 ^HKD	-4,17 %		+6,15 %	-44,35 %

08.04.	Der RSV-Impfstoffkandidat von Clover Biopharmaceuticals zeigt vielversprechende Ergebnisse in einer frühen Studie	MT
08.04.	Clover Biopharmaceuticals, Ltd. gibt positive vorläufige Phase I-Ergebnisse für den bivalenten RSV-Impfstoffkandidaten SCB-1019 in der ersten Kohorte junger Erwachsener bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding	12.04.
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial	08.04.
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort	08.04.
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 In Initial Young Adult Cohort	08.04.
Clover Biopharmaceuticals, Ltd. announced that it expects to receive $0.320713 million in funding	02.04.
Clover Biopharmaceuticals Trims Losses in 2023	27.03.
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	12.01.
Clover Announces Positive Phase ? Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)	29.12.
Clover Biopharmaceuticals Publishes Positive Results from SCB-219M Clinical Trial	29.12.
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia	29.12.
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5%	13.12.
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate	13.12.
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate	13.12.
Clover Biopharmaceuticals Completes Submission of Application for Seasonal Flu Vaccine in Brazil	07.11.
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil	07.11.
Clover Biopharmaceuticals Rolls Out Quadrivalent Seasonal Influenza Vaccine in Mainland China	12.09.23
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12.09.23
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12.09.23
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Clover Biopharmaceuticals, Ltd.

Aktien

A3C6A8

KYG2280A1076

2197

Andere Sprachen

Filter